Trevi Therapeutics, Inc. Common Stock US Stock
Open: $2.23 High: $2.24 Low: $2.01 Close: $2.01
Range: 2022-06-27 - 2022-06-28
Market: Extended-hours
Trevi Therapeutics, Inc. Common Stock 195 CHURCH STREET
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. It is involved in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinson's disease.
  • CEO:
  • Employees: 23
  • Sector:
  • Industry:
Latest Stocks Posts
Card image
Card image
Card image
Latest news about the TRVI